KalVista sees a win in PhII for the rare genetic disorder HAE as it continues to chart a post-Merck course

Roughly a year after Merck walked away from a partnership with KalVista following a flop in diabetic macular edema, the biotech is back with data …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

KalVista sees a win in PhII for the rare ge­net­ic dis­or­der HAE as it con­tin­ues to chart a post-Mer­ck course